BLOG

With $45M Nurix Deal, Gilead Enters Crowded Protein Degradation Field

Gilead Sciences is turning to Nurix Therapeutics in an effort to discover new drugs that harness the cellular machinery our bodies use to dispose of damaged or harmful proteins.